RecruitingPHASE2, PHASE3NCT04256317
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Studying Acute myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Taiho Oncology, Inc.
- Intervention
- Azacitidine(drug)
- Enrollment
- 316 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2028
Study locations (30)
- Keck School of Medicine of USC, Los Angeles, California, United States
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange, California, United States
- Yale University, New Haven, Connecticut, United States
- University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- University of Emory - Winship Cancer Institute, Atlanta, Georgia, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- John Theurer Cancer Center / Hackensack University, Hackensack, New Jersey, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- New York University Langone Hospital - Long Island, Mineola, New York, United States
- Perlmutter Cancer Center - 34th Street, New York, New York, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Weill Cornell Medical Center, New York, New York, United States
- University of Rochester - Wilmot Cancer Center, Rochester, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Duke University, Durham, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04256317 on ClinicalTrials.govOther trials for Acute myelomonocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06994676A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasCrossbow Therapeutics, Inc.
- RECRUITINGPHASE2NCT06680661ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisLeland Metheny
- RECRUITINGPHASE2NCT06778187Oral-ATO for TP53-mutated Myeloid MalignanciesThe University of Hong Kong
- RECRUITINGPHASE1NCT06247787A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyChildren's Oncology Group
- RECRUITINGNCT06111612Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT05807932Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE1NCT05636514Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSClinical Hub for Interventional Research (CHOIR)
- RECRUITINGPHASE1, PHASE2NCT05092451Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesM.D. Anderson Cancer Center